Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
The purpose of this study is to better understand how cancer treatment of Enzalutamide (MDV3100) may affect prostate cancer cells. The research will involve genetic, molecular, cellular and immunologic experiments using blood and tumor specimens. It is hoped that the information gained from these studies will lead to a greater understaning of castrate-resistant prostate cancer, Enzalutamide resistance and potentially, improvements in cancer treatment.
Metastatic Prostate Cancer that no longer responds to hormaone therapy.
Prostate cancer that has spread outside the prostate who are eligible to but not yet started treatment with Enzalutamide.
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will have study visits when you first start taking Enzalutamide, at week 6 and week 12 after starting Enzalutamide treatment and then every subsequent 12 weeks until your cancer stops responding to Enzalutamide treatment (about 6 months to 3 years). We will continue to check on you by telephone for the rest of your life.
Cancer trials information line: Phone 503-494-1080 or email@example.com
DOD, Stand Up To Cancer - Prostate Cancer Foundation